Table 2.
Cytokine secretion was significantly altered by VX765 treatment compared to LPS/Nigericin treatment (p < 0.05).
| Cell line | Regulation of cytokine release in VX765 treated cells compared to LPS/Nigericin treated cells | |
|---|---|---|
| Increased cytokine release | Decrease cytokine release | |
| A549 | IL6, CXCL10, CXCL11, CCL1, CCL8, CCL11, CCL13, CCL22,CCL24, CCL26, CCL27, TNFa | |
| MCF7 | - | IL10, IL16, IFNg, CXCL2, CXCL6, CXCL9,CCL21, CXCL10, CXCL11, CXCL13,CCL1, CCL7, CCL11, CCL20, CCL23, CCL25, MIF |
| PC3 | CCL24 | IL2, IL4, IL6, IL10, IL16, IFNg, CXCL9, CXCL12, CXCL13, CCL7, CCL8, CCL11, CCL15, CCL19, CCL21, CCL22, CCL23, CCL25, TNFa |
| SH-SY5Y | IL4, IFNg, CXCL1, CX3CL1, CXCL8, CXCL11, CXCL16, CCL5, CCL7, CCL13, GMCSF | - |
| U138 | - | IL2, IL4, IL6, IL16, CXCL2, CXCL3, CXCL6, CXCL9, CXCL10, CCL1, CCL7, CCL17, CCL20, CCL25, CCL26, CCL27, GMGSF, IFNg, MIF, TNFa |